VCG
EW icon

Vantage Consulting Group’s Edwards Lifesciences EW Stock Holding History

Vantage Consulting Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-710
Closed -$65K – 574
2020
Q4 		$65K Buy
+710
New +$58.9K 0.01% 350

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vantage Consulting Group's EW Position: Q1 2021 in Review

Vantage Consulting Group sold out of Edwards Lifesciences (EW) in Q1 2021, closing a stake of 710 shares — an estimated $65K sold.

Vantage Consulting Group first reported a position in EW in Q4 2020 and held it in 1 quarter. The position peaked at $65K in Q4 2020. 1,143 funds tracked by Wall St. Rank hold EW as of Q1 2021.

  • Vantage Consulting Group reported no remaining Edwards Lifesciences position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 710 Edwards Lifesciences shares in Q1 2021, an estimated $65K.
  • Vantage Consulting Group first reported a position in Edwards Lifesciences in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Edwards Lifesciences position peaked at $65K in Q4 2020.
  • 1,143 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.